Recommended

Ph. Eur. Commission updates mAb standards
FDA approves Omisirge cell therapy for severe aplastic anaemia
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
Pfizer $2bn GLP-1 YaoPharma deal
Lilly furthers US onshoring with new manufacturing facility
Europe makes progress in agreeing new pharma legislation
J&J biologics demonstrate potential in multiple myeloma
Moderna expands mRNA drug delivery capabilities
WEBINAR: reflections and future opportunities in pharmaceutical microbiology
CSL invests $1bn in new vaccine manufacturing facility
CHMP recommends two new cancer drugs in Dec 2025 meeting

List view / Grid view

News

Janssen pharmaceuical companies of Johnson & Johnson
Janssen pharmaceuical companies of Johnson & Johnson

New follow-up data for IMBRUVICA® (ibrutinib) presented at ASH show longer term efficacy in patients with chronic lymphocytic Leukaemia and mantle cell lymphoma

10 December 2014 | By Janssen

Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term follow-up data from two IMBRUVICA® (ibrutinib) studies at the American Society of Hematology (ASH) meeting in San Francisco, CA. IMBRUVICA is a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.

Red pills in foil pack
Red pills in foil pack

Pricing for new drugs lacks transparency

10 December 2014 | By The Royal Society of Medicine

The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers...

Roche logo
Roche logo

Roche presents data for hemophilia A therapy ACE910

9 December 2014 | By Roche

Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting...

Eli Lilly logo
Eli Lilly logo

Scottish Medicines Consortium accepts use of Alimta (pemetrexed) for treatment of non-small cell lung cancer

9 December 2014 | By Eli Lilly and Company

On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (other than predominantly squamous cell histology) in patients whose disease has not progressed immediately following platinum-based chemotherapy...

GlaxoSmithKline logo
GlaxoSmithKline logo

GSK presents asthma data that shows no additional clinical efficacy benefits for ICS-treatments with a small particle size

9 December 2014 | By GSK

GSK presented data at the British Thoracic Society meeting from a systematic analysis of 25 randomised control studies (RCTs), including a meta-analysis of three key efficacy outcomes, which explored the potential impact of the particle size of different ICS-containing asthma medicines, including Seretide/Advair (salmeterol/fluticasone proprionate) on patient outcomes...